Update on SECURE trial safety review

Clarity Pharmaceuticals (ASX:CU6) has provided an update on the safety review of the SECURE trial's cohort 4. The trial, aimed at identifying and treating participants with prostate-specific membrane antigen (PSMA)-expressing metastatic castrate-resistant prostate cancer, has shown no dose limiting toxicities and strong preliminary efficacy data in the first multi-dose cohort.

Executive Commentary on SECURE Trial Results

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, expressed satisfaction with the safety profile and efficacy data from cohort 4 of the SECURE trial. He highlighted the excellent safety profile for 67Cu-SAR-bisPSMA and the outstanding response to treatment, even in patients who had failed multiple lines of therapies. Dr Taylor emphasized the potential for early-stage treatment and the Company's ambitions to address the high unmet need in prostate cancer patients.

Summary of SECURE Trial Update

The SECURE trial's cohort 4 has demonstrated a positive safety profile and significant reduction in PSA levels in prostate cancer patients. The preliminary efficacy assessment showed a reduction of more than 60% in PSA levels in participants following their second dose. Clarity Pharmaceuticals plans to progress to the Phase II stage of the trial, pending safety evaluation, and is optimistic about the potential for 67Cu-SAR-bisPSMA in treating prostate cancer. The Company aims to focus on earlier stages of prostate cancer treatment and is encouraged by the speed of clinical trial recruitment and the product's potential to positively impact patients' lives.